SCHEMBL6783293

SCHEMBL6783293

CCOC(=O)C(Cc1ccc2c(c1)OCO2)NC(=O)CNC(=O)c1cccc(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.54
RAB9A P51151 7/20 0.53
NPC1 O15118 5/20 0.53
PAX8 Q06710 1/20 0.48
KLF5 Q13887 1/20 0.48
CHRM2 P08172 3/20 0.47
CHRM1 P11229 3/20 0.47
CHRM3 P20309 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 1/20 0.46
MMP13 P45452 1/20 0.46
TSHR P16473 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778765 0.94 HSD17B10 (0.55) HSD17B10RAB9ANPC1MEN1KMT2A
SCHEMBL7338950 0.90 HSD17B10 (0.56) HSD17B10RAB9ANPC1PAX8KLF5
SCHEMBL7825264 0.86 HSD17B10 (0.47) HSD17B10RAB9ANPC1MEN1KMT2A
SCHEMBL7377590 0.83 GSK3B (0.58) HSD17B10RAB9ANPC1MEN1KMT2A
SCHEMBL6773783 0.82 NAMPT (0.52) ALDH1A1MAPTLMNAMAPK1TP53
SCHEMBL7835626 0.81 TSHR (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL7833465 0.79 ITGB3 (0.44) HSD17B10MEN1KMT2ALMNAMAPK1
SCHEMBL6778762 0.78 ITGB3 (0.51) HSD17B10RAB9ANPC1MEN1KMT2A
SCHEMBL6778759 0.78 TP53 (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL7824027 0.78 GPR139 (0.48) RAB9ANPC1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed